The aim of our study to evaluate the effect of ZAP-70 and CD38 independently as well as combined expression of both together in B-CLL patients and their influence in clinical features, hematological parameters and at a stage of presentation, accordingly our patients are divided into three groups. This evidence concerns the gene ZAP70 and B-cell chronic lymphocytic leukemia.